title: Effect of dexamethasone on perioperative renal function impairment during cardiac surgery with cardiopulmonary bypass.
abstract: BACKGROUND
  In cardiac surgery with cardiopulmonary bypass (CPB), corticosteroids are administered to attenuate the physiological changes caused by the systemic inflammatory response. The effects of corticosteroids on CPB-associated renal damage have not been documented. The purpose of this study was to evaluate the effects of dexamethasone on perioperative renal dysfunction in patients undergoing cardiac surgery with CPB.
  
  
  METHODS
  Renal damage was prospectively studied in 20 patients without concomitant morbidity undergoing coronary artery surgery with CPB. Patients were randomized in a double-blind fashion to receive dexamethasone or placebo. Markers of glomerular function (creatinine clearance) and damage (microalbuminuria), and markers of tubular function (fractional excretion of sodium and free water clearance) and damage (N-acetyl-beta-D glucosaminidase (NAG)) were evaluated in addition to plasma and urinary glucose levels. Plasma and urinary specimens were obtained at the following time periods: (1) baseline, during the 12 h before surgery; (2) skin incision before heparinization; (3) from heparinization until the end of CPB; (4) during the 2 h following weaning from CPB; (5) in the intensive care unit from 2 to 6 h after weaning of CBP; (6) and from 36 to 60 h after weaning of CPB.
  
  
  RESULTS
  CPB was associated with an increase in markers in the placebo group, which returned to baseline during the second postoperative day, demonstrating a transient impairment of glomerular and tubular renal function. Similar patterns were observed in patients treated with dexamethasone. While postoperative glycosuria was significantly higher in the dexamethasone-treated group, no other differences between groups were observed.
  
  
  CONCLUSIONS
  Dexamethasone administration before CPB has no protective effect on perioperative renal dysfunction in low-risk cardiac surgical patients.
authors.affiliation: Cardiothoracic Intensive Care Unit, University Hospital Groningen, Groningen, The Netherlands. b.g.loef@thorax.azg.nl
authors.forename: B G
authors.initials: BG
authors.lastname: Loef
authors.forename: R H
authors.initials: RH
authors.lastname: Henning
authors.forename: A H
authors.initials: AH
authors.lastname: Epema
authors.forename: G W
authors.initials: GW
authors.lastname: Rietman
authors.forename: W
authors.initials: W
authors.lastname: van Oeveren
authors.forename: G J
authors.initials: GJ
authors.lastname: Navis
authors.forename: T
authors.initials: T
authors.lastname: Ebels
mesh_terms: D000368:Aged; D000419:Albuminuria / Q000188:drug therapy; D015415:Biomarkers / Q000652:urine; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D001026:Coronary Artery Bypass; D003404:Creatinine / Q000652:urine; D003907:Dexamethasone / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011229:Preanesthetic Medication; D011446:Prospective Studies
chemical_list: D015415:Biomarkers; D005938:Glucocorticoids; D003907:Dexamethasone; D003404:Creatinine